Efficacy of HEAR and HEART score to rule out major adverse cardiac events in patients presenting to the emergency department with chest pain: study protocol of the eCARE stepped-wedge randomised control trial.

Moumneh, Thomas;Penaloza-Baeza, Andrea;Charpentier, Sandrine;Douillet, Delphine;Roy, Pierre-Marie;et.al.
(2022) BMJ open — Vol. 12, n° 12, p. e066953 [1-7] (2022)

Files

2022_Moumneh_BMJ_Open.pdf
  • Open Access
  • Adobe PDF
  • 470.65 KB
Download

Details

Authors
  • Moumneh, Thomasorcid-logo
    Author
  • Penaloza-Baeza, AndreaUCLouvain
    Author
  • Charpentier, Sandrine
    Author
  • Douillet, Delphine
    Author
  • Roy, Pierre-Marieorcid-logo
    Author
Show more
Abstract
INTRODUCTION: Current guidelines for patients presenting to the emergency department (ED) with chest pain without ST-segment elevation myocardial infarction (STEMI) on ECG are based on serial troponin measurements. A clinical tool able to identify very low-risk patients who could forgo a troponin test and low-risk patients requiring only one troponin measurement would be of great interest. To do so, the HEAR and HEART score, standing for history, ECG, age, risk factors±troponin were prospectively assessed, but not combined and implemented in clinical practice. The objective of the eCARE study is to assess the impact of implementing a diagnostic strategy based on a HEAR score <2 or a HEART score <4 (HEAR-T strategy) to rule out non-STEMI without or with a single troponin measurement in patients presenting to the ED with chest pain without obvious diagnosis after physical examination and an ECG. METHODS AND ANALYSIS: Stepped-wedge cluster-randomised control trial in 10 EDs. Patients with non-traumatic chest pain and no formal diagnosis were included and followed for 30 days. In the interventional phase, the doctor will be asked not to perform a troponin test to look for an acute coronary if the HEAR score is <2 and not to perform an additional troponin test if the HEAR score is ≥2 and HEART score is <4. The main endpoint is the non-inferiority of the rates of major adverse cardiac events occurring between a patient's discharge and the 30-day follow-up against current recommended guidelines. ETHICS AND DISSEMINATION: The study was approved by an institutional review board for all participating centres. If successful, the eCARE study will cover a gap in the evidence, proving that it is safe and efficient to rule out the hypothesis of an acute myocardial infarction in some selected very low-risk patients or based on a single troponin measurement in some low-risk patients. TRIAL REGISTRATION NUMBER: NCT04157790.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Moumneh, T., Penaloza-Baeza, A., Charpentier, S., Douillet, D., Prunier, F., Riou, J., & Roy, P.-M. (2022). Efficacy of HEAR and HEART score to rule out major adverse cardiac events in patients presenting to the emergency department with chest pain: study protocol of the eCARE stepped-wedge randomised control trial. BMJ open, 12(12), e066953 [1-7]. https://doi.org/10.1136/bmjopen-2022-066953 (Original work published 2022)